Cancer Drugmaker BlossomHill Declines After $150 Million US IPO

BlossomHill Therapeutics raises $150 million in upsized oncology IPO

Oncology-focused biotech firm BlossomHill Therapeutics raised $150 million in an upsized U.S. initial public offering, though shares fell 1.6% in their trading debut.